Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 4/20 | 0.56 |
| ▸ | MKNK2 | Q9HBH9 | 4/20 | 0.56 |
| ▸ | DRD4 | P21917 | 8/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | DRD2 | P14416 | 7/20 | 0.46 |
| ▸ | DRD3 | P35462 | 6/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.43 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
| ▸ | IGF1R | P08069 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14985535 | 0.93 | MKNK1 (0.52) | MKNK1MKNK2DRD4MEN1KMT2A | |
| SCHEMBL19806143 | 0.80 | MKNK1 (0.82) | MKNK1MKNK2DRD4MEN1KMT2A | |
| SCHEMBL3346937 | 0.79 | MKNK1 (0.51) | MKNK1MKNK2DRD4MEN1KMT2A | |
| SCHEMBL8415608 | 0.78 | NPC1 (0.56) | MEN1KMT2AIGF1R | |
| SCHEMBL19805568 | 0.76 | DRD4 (0.76) | MKNK1MKNK2DRD4MEN1KMT2A | |
| SCHEMBL3346932 | 0.75 | USP30 (0.47) | MKNK1MKNK2DRD4MEN1KMT2A | |
| SCHEMBL25431152 | 0.73 | MKNK1 (0.59) | MKNK1MKNK2DRD4MEN1KMT2A | |
| SCHEMBL14985532 | 0.73 | MAPT (0.46) | POLBHCAR2IGF1R | |
| SCHEMBL14985509 | 0.73 | MKNK1 (0.76) | MKNK1MKNK2DRD4MEN1KMT2A | |
| SCHEMBL14985523 | 0.73 | COMT (0.44) | IGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190292179-A1 | TGF Beta RECEPTOR ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2019-09-26 | — | — | US | disclosed |
| WO-2018017633-A1 | TGF Beta RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-01-25 | — | — | WO | disclosed |
| EP-2788086-B1 | SUBSTITUTED PYRAZOLES AS MGLU5 RECEPTOR MODULATORS | BOEHRINGER INGELHEIM INT (DE) | 2016-10-12 | — | — | EP | disclosed |
| EP-2785696-B1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INT (DE) | 2015-09-23 | — | — | EP | disclosed |
| US-8822464-B2 | N-aryl-piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-09-02 | — | — | US | disclosed |
| WO-2013083591-A1 | SUBSTITUTED PYRAZOLES AS MGLU5 RECEPTOR MODULATORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-13 | — | — | WO | disclosed |
| WO-2013079460-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-06 | — | — | WO | disclosed |
| US-20130143870-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-06 | — | — | US | disclosed |
| US-20130137688-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190292179-A1 | TGF Beta RECEPTOR ANTAGONISTS | TGFBR1, TGFBR2, TGFB1 | MKNK1 1265/4885MKNK2 1286/4885DRD4 4295/4885 |
| US-20130137688-A1 | NOVEL COMPOUNDS | GRM5, GRIN1, GRM1 | MKNK1 1316/4885MKNK2 1130/4885DRD4 250/4885 |
| US-20130143870-A1 | NOVEL COMPOUNDS | GRM5, GRM1, GRIK5 | MKNK1 1349/4885MKNK2 1123/4885DRD4 320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.